wellrank.ai
Femring logo

Femring

First cited by AI Jun 13, 2026

Surfaced organically in AI answers about menopause and women's health. Not yet profiled.

AI Visibility

Visibility trend

Menopause and women's health, daily share of AI answers mentioning Femring, through Jun 13, 2026.

8.3%

Avg position when mentioned: 9.0

By engine

Where Femring is strong, and where it is invisible.

  • ChatGPT
    33.3%

Mention sentiment

Tone of AI mentions across all tracked answers.

  • 1 positive mentions
  • 0 neutral
  • 0 mixed or cautious

Recent AI answers mentioning Femring

ChatGPTJun 13, 2026, 11:06 UTC
Bioidentical hormones vs standard HRT: what is the difference?

Short answer “Bioidentical” hormones are molecules formulated to be chemically identical to the hormones your body makes (usually estradiol and progesterone). “Standard” HRT (hormone replacement therapy) includes both bioidentical (FDA‑approved) products and older synthetic or animal‑derived products; the main practical difference most people face is whether the product is an FDA‑reviewed drug or a custom‑compounded preparation from a pharmacy. There’s no good evidence that custom‑compounded “bioidentical hormone therapy” is safer or more effective than FDA‑approved HRT. Compounded products can have variable potency and lack FDA oversight. What each term means Bioidentical hormones: chemically identical to human hormones (example: 17β‑estradiol, micronized progesterone). These can be made as FDA‑approved products (tablets, patches, gels, vaginal rings) or as custom compounds from compounding pharmacies. Standard HRT: a broader category that includes FDA‑approved estradiol products (patches, gels, pills) and FDA‑approved micronized progesterone, synthetic progestins (e.g., medroxyprogesterone acetate) and animal‑derived estrogens (e.g., conjugated equine estrogens). These are manufactured drugs with standardized dosing and safety testing. Examples (brand names and why they matter) FDA‑approved, bioidentical examples: Prometrium (micronized progesterone) — FDA‑approved bioidentical progesterone used to protect the uterus when systemic estrogen is given. Estradiol patches/gels: Vivelle‑Dot, Climara, Alora — deliver 17β‑estradiol transdermally and have standardized dosing. Bijuva — an FDA‑approved combined oral capsule containing estradiol and progesterone (bioidentical combination). Vaginal products: Estrace cream, Vagifem tablets, Estring/Femring (vaginal ring/locally acting estradiol) — useful for local symptoms with lower systemic exposure. Non‑bioidentical / synthetic examples: Premarin (conjugated equine estrogens) — animal‑derived estrogen mixture, historically common. Provera (medroxyprogesterone acetate) — synthetic progestin. Compounded “bioidentical” creams or troches: made by compounding pharmacies to a custom dose. These are not FDA‑approved and product strength/purity can vary. If you choose this route, use a PCAB‑accredited compounding pharmacy (look up PCAB accreditation). Examples of well‑known compounding suppliers/pharmacies in the U.S. include Wedgewood Pharmacy and Fagron (as suppliers/compounding networks) — but check current accreditation and reputation locally. Safety, evidence, and regulation FDA‑approved HRT products have known dosages, standardized manufacturing, and have been evaluated for quality and safety. Long‑term risks (breast cancer, cardiovascular disease, stroke, blood clots) depend on the type of hormone, dose, route (oral vs transdermal), whether progesterone is given, and your personal risk factors. The Women’s Health Initiative (WHI) showed increased risks with combined conjugated equine estrogen + medroxyprogesterone in older participants. Risk profiles differ with estradiol vs conjugated equine estrogens and with micronized progesterone vs synthetic progestins. Compounded bioidenticals: proponents claim “natural” = safer, but there’s no high‑quality evidence that compounded BHRT reduces long‑term risks. Because compounded products aren’t FDA‑reviewed, potency and purity can be inconsistent and they may lack safety data. Testing and monitoring Beware of clinics that base dosing on saliva tests or single spot hormone levels — hormone levels fluctuate and those tests are not reliable for routine dosing. Appropriate approach: evaluate symptoms, medical history, family history (breast cancer, clotting disorders), baseline screening (mammogram, blood pressure, lipids, glucose as needed), then choose a therapy and monitor symptoms and side effects regularly. Use the lowest effective dose for the shortest needed time, and use uterine protection (progesterone or a progestin) if you have a uterus and take systemic estrogen. Practical guidance / when to prefer one option If you want the assurance of standardized dosing and known safety data, choose FDA‑approved products (e.g., estradiol patches, oral estradiol, Prometrium, Bijuva). Consider local vaginal estrogen (Estrace cream, Vagifem, Estring) for primarily vaginal dryness/urginal symptoms — these have lower systemic exposure. If you have unusual needs (allergies to excipients, very specific dose requests), a compounding pharmacy can be considered — but insist on a reputable, PCAB‑accredited pharmacy and understand the tradeoffs (no FDA approval, variable evidence). Discuss the choice with a clinician experienced in menopause/HRT care (board‑certified gynecologist or endocrinologist). Trusted resources: North American Menopause Society (NAMS), Mayo Clinic, Cleveland Clinic for patient information and evidence‑based guidance. Bottom line “Bioidentical” describes the molecular structure of the hormone; the clinically important distinction is whether the product is an FDA‑approved, standardized medication or a custom, non‑FDA‑regulated compounded product. FDA‑approved bioidentical options (Prometrium, estradiol patches/creams, Bijuva) give predictable dosing and safety data; compounded BHRT may be useful in select cases but carries more uncertainty. Talk with a clinician about your symptoms, risks, and monitoring plan before starting HRT.

Mentioned in position 9 of 13

Read full answer with sources →

Public AI visibility history

Daily rank of Femring on our buyer intent questions, per category. A dash means the engines did not cite Femring at all that day. This record is permanent.

CategoryJun 11Jun 12Jun 13
Menopause and women's health#33

TL;DR

Femring is a prescription vaginal ring containing estradiol acetate, indicated for treating moderate to severe vasomotor symptoms and vulvovaginal atrophy associated with menopause. It is manufactured and marketed as a systemic hormone therapy option delivering estrogen locally via a flexible silicone ring worn for three months at a time. In WellRank's latest index, Femring ranks 12th in the Menopause and women's health category with 8% AI visibility, and the single AI mention captured in our corpus carries a positive tone.

Company Overview

Femring is a branded prescription product, not a standalone company. It was developed and has been distributed under the Warner Chilcott and later Allergan (now AbbVie) umbrella, though exact current ownership details are not always prominently publicized. The product is sold through the traditional pharmaceutical distribution model, requiring a licensed prescriber and dispensed via retail or specialty pharmacies. Its business model is that of a branded pharmaceutical product competing within the hormone therapy segment of women's health.

Product Features

  • A soft, flexible vaginal ring delivering estradiol acetate, a prodrug of estradiol, over a three-month wear period
  • Provides systemic estrogen exposure, distinguishing it from locally acting low-dose rings such as Estring
  • Indicated for moderate to severe vasomotor symptoms including hot flashes as well as vulvovaginal atrophy
  • Available in two estradiol acetate dose strengths to allow prescriber titration
  • Designed for continuous, patient-managed use with quarterly ring replacement

Target Market

Femring is indicated for postmenopausal women experiencing moderate to severe hot flashes or symptoms of vaginal atrophy who are candidates for systemic estrogen therapy. It is a prescription product available in the United States. Women who prefer a discreet, long-acting delivery method over daily pills or topical applications represent its primary clinical target.

Buyer Personas

  • A perimenopausal or postmenopausal woman in her late 40s to 60s seeking a convenient, set-and-forget hormone therapy that does not require daily administration.
  • A gynecology patient who has discussed hormone therapy options with her physician and prefers a non-oral route to avoid first-pass liver metabolism.
  • A woman experiencing both vasomotor symptoms and vaginal atrophy who wants a single systemic treatment addressing both conditions.
  • A health-conscious patient already familiar with vaginal rings from contraceptive use and comfortable with intravaginal drug delivery.

Funding & Performance

Femring is a branded pharmaceutical product whose financial performance, sales figures, and revenue contribution are not publicly disclosed as a standalone line item. Its parent commercial history traces through Warner Chilcott and Allergan to AbbVie following a series of acquisitions, all of which are large, publicly traded entities, but Femring-specific financials are not published.

Recent Developments

Generic versions of estradiol acetate vaginal rings have entered the market over time, increasing competitive pressure on the branded Femring product. The broader women's health and menopause treatment category has seen renewed clinical and commercial interest as updated guidance from professional societies has encouraged more open conversations about hormone therapy. No major branded reformulations or new indications for Femring have been widely publicized in recent periods.

Competitive Landscape

Femring competes primarily within the hormone therapy segment of women's health, where WellRank co-mention data shows it appears alongside Estring, Vagifem, Vivelle-Dot, Premarin, Prometrium, and Provera in AI-generated answers. Estring is its most direct product-format competitor, though Estring delivers a lower, locally acting estradiol dose rather than systemic levels. Compounding pharmacies such as Wedgewood Pharmacy and Fagron also appear in the same AI answer space, reflecting patient and prescriber interest in customized hormone formulations as alternatives to branded options.

Femring vs the brands AI recommends alongside it

The real competitive set in Menopause and women's health: brands the engines name in the same answers, ranked on the latest day.

BrandRankAI visibility
Femring logo
FemringThis brand
#33
8.3%
Alora logo
Alora

1 shared answers

#29
8.3%
Bijuva logo
Bijuva

1 shared answers

#16
8.3%
Climara logo
Climara

1 shared answers

#7
16.7%
Estrace logo
Estrace

1 shared answers

#8
16.7%

Email me when overtakes Femring

One email the day the ranks flip. Nothing else.

User Sentiment

Based on WellRank's corpus, Femring has one captured AI mention and it is positive in tone, with no neutral or cautious mentions recorded at this time. Broader patient-facing discussions tend to highlight the convenience of the three-month ring format and the product's ability to address both systemic and local menopausal symptoms, though individual tolerability and the need for ongoing progestogen co-therapy in women with a uterus are commonly noted clinical considerations.

Pricing

Pricing for Femring varies and is not published in a standardized way. As a branded prescription product, out-of-pocket cost depends heavily on insurance coverage, pharmacy benefit design, and whether a patient qualifies for any manufacturer savings programs. Patients without coverage can expect branded hormone therapy products to carry a meaningful out-of-pocket cost; exact figures are not stable enough to cite reliably.

Sources cited around Femring

The sites engines cite in answers mentioning this brand. Win these, win the answer.

    Track Femring weekly

    One email a week: rank moves, new competitors, and the answers that changed. No noise.

    Work at Femring? Get your AI Visibility Audit.

    See every buyer intent question your customers ask AI, which ones you are losing, who wins them instead, and the exact sources driving those answers. You will finally understand your buyer intent and what Propel would do to win it.